News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,434 Results
Type
Article (14053)
Company Profile (283)
Press Release (249098)
Section
Business (79424)
Career Advice (152)
Deals (13212)
Drug Delivery (34)
Drug Development (50378)
Employer Resources (31)
FDA (5699)
Job Trends (5120)
News (144243)
Policy (10023)
Tag
Academia (901)
Alliances (21589)
Alzheimer's disease (783)
Antibody-drug conjugate (ADC) (70)
Approvals (5687)
Artificial intelligence (90)
Bankruptcy (99)
Best Places to Work (4550)
Biotechnology (232)
Breast cancer (123)
Cancer (1040)
Cardiovascular disease (84)
Career advice (132)
CAR-T (86)
Cell therapy (248)
Clinical research (40421)
Collaboration (400)
Compensation (155)
COVID-19 (1019)
C-suite (104)
Cystic fibrosis (72)
Data (1073)
Diabetes (98)
Diagnostics (1245)
Earnings (29084)
Events (47473)
Executive appointments (326)
FDA (6146)
Funding (379)
Gene editing (72)
Gene therapy (187)
GLP-1 (335)
Government (1069)
Healthcare (6560)
Infectious disease (1060)
Inflammatory bowel disease (100)
IPO (7233)
Job creations (859)
Job search strategy (127)
Layoffs (194)
Legal (1381)
Lung cancer (154)
Manufacturing (95)
Medical device (2566)
Medtech (2567)
Mergers & acquisitions (6185)
Metabolic disorders (298)
Neuroscience (1078)
NextGen: Class of 2025 (2013)
Non-profit (851)
Northern California (1243)
Obesity (162)
Opinion (93)
Parkinson's disease (86)
Patents (72)
People (25276)
Phase I (14270)
Phase II (18795)
Phase III (11886)
Pipeline (462)
Postmarket research (852)
Preclinical (5983)
Radiopharmaceuticals (208)
Rare diseases (231)
Real estate (1411)
Regulatory (8381)
Research institute (932)
Series A (75)
Southern California (1115)
Startups (1968)
United States (9847)
Vaccines (177)
Weight loss (94)
Date
Today (12)
Last 7 days (379)
Last 30 days (1580)
Last 365 days (20392)
2025 (1607)
2024 (20553)
2023 (22415)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10393)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (17040)
Australia (2883)
California (2838)
Canada (895)
China (255)
Colorado (106)
Connecticut (118)
Delaware (65)
Europe (36657)
Florida (320)
Georgia (84)
Illinois (180)
Indiana (69)
Maryland (371)
Massachusetts (2249)
Minnesota (113)
New Jersey (707)
New York (781)
North Carolina (450)
Northern California (1243)
Ohio (91)
Pennsylvania (536)
South America (207)
Southern California (1115)
Texas (316)
Washington State (272)
263,434 Results for "aldeyra therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
December 2, 2024
·
1 min read
Press Releases
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
November 14, 2024
·
1 min read
Genetown
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aldeyra Therapeutics, Inc. today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference.
May 29, 2024
·
1 min read
Genetown
Aldeyra Therapeutics to Host Investor Roundtable Q&A
Aldeyra Therapeutics, Inc., a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET.
June 12, 2024
·
1 min read
Drug Development
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics, Inc. announced the completion of enrollment in a Phase 3 dry eye chamber clinical trial of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease.
June 13, 2024
·
8 min read
Genetown
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
Aldeyra Therapeutics, Inc. today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today.
June 20, 2024
·
8 min read
Genetown
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Aldeyra Therapeutics, Inc.today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City.
April 18, 2024
·
1 min read
Press Releases
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
October 31, 2024
·
1 min read
Genetown
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
April 25, 2024
·
8 min read
Press Releases
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
October 3, 2024
·
8 min read
1 of 26,344
Next
